x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAA-001324
| Product Information | |
|---|---|
| Product Name | Rat Osteoprotegerin ELISA Kit (OPG) |
| Species | Rat |
| Description | Rat Osteoprotegerin ELISA Kit (OPG) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Osteoprotegerin (OPG) protein in cit plasma, edta plasma, hep plasma, and serum. It uses our proprietary ELISA technology. Quantitate Rat Osteoprotegerin (OPG) with 30 pg/mL sensitivity ELISA technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our ELISA plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. |
| Sample Types | Serum, Hep Plasma, Edta Plasma, Cit Plasma |
| Detection Range | 46.88 pg/mL - 3000 pg/mL |
| Sensitivity | 30 pg/mL |
| Target Information | |
|---|---|
| Target Name | TNFRSF11B |
| UniProt No. | O00300 |
| Gene ID | 4982 |
| Target Description | Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. |
| Alternative Names | MGC29565; OCIF; OPG; Osteoclastogenesis inhibitory factor; Osteoprotegerin; PDB5; TNF receptor superfamily member 11b; TNFRSF 11B; TNFRSF11B; TR 1; TR1; TR11B_HUMAN; Tumor necrosis factor receptor superfamily member 11B |
| Shipping & Storage | |
|---|---|
| Sipping | Shipping on dry ice. |
| Storage | Store at +4°C. Please refer to protocols. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
